Allied Healthcare Group Ltd : First CardioCel sales in EU

ASX ANNOUNCEMENT

Brisbane, Australia, 8th November 2013

Allied Healthcare Group (ASX: AHZ) today announces it has commenced shipment of CardioCel®
into Europe after the Company received its first orders for the product from outside of Australia.
In August the Company received European CE mark approval for CardioCel® and so cleared the final regulatory hurdle ahead of a launch and marketing of the product in this key market.
"Today we can announce we have made the first sale of CardioCel® into Europe and shipping has commenced - a milestone development for both the Company and our lead regenerative tissue product," said Allied Healthcare Group's CEO Mr Lee Rodne.
"Allied is seeking to have CardioCel® used by cardiothoracic surgeon teams across Europe for the repair and reconstruction of cardiac defects in both adults and children.
"We will initially focus our European sales team on the major centers across Europe as we aim to
build our market penetration over the next 12 to 36 months."
CardioCel® is available for use by surgeons in Australia via an authorized prescriber scheme. It has been shown to offer a range of benefits over alternative products including a strong level of regeneration of tissue, lack of cytotoxicity and calcification at the site of repair. It is also an off- the-shelf ready product with improved elasticity that makes CardioCel® more user-friendly for surgeons.
Allied is expecting significant growth in Group earnings over the coming 12 months to 3 years as it continues to grow revenue from its infusion product portfolio and its regenerative tissue programs.
The Company also has plans to expand its regenerative tissue portfolio with additional tissue products for cardiovascular repair and reconstruction, vessel repair & conduits; as well as other applications like cellular therapies, hernia and pelvic floor repair.
Allied also continues to progress well with its 510(K) application for CardioCel® with the FDA. The Company anticipates US marketing approval in 2014.

Dr Julian Chick, Chief Operating Officer Allied Healthcare Group Tel: +61 3 9620 5454
Media: Haley Price
Buchan Consulting
+61 39866 4722 scooper@buchanwe.com.au

ABN 35 088 221 078

Level 1, 197 Adelaide Terrace

Perth Western Australia 6000

PO Box 6879 East Perth

Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

E info@alliedhealthcaregroup.com.au

Allied Healthcare Group Limited (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical sales and distribution business. The Company has assets from research & development through clinical development as well as sales, marketing and distribution.
Allied Healthcare Group is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Allied also has a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programs target disease with significant global potential such as Herpes and Human Papillomavirus.
Further information on the Company can be found on www.alliedhealthcaregroup.com.au.

Allied's regenerative tissue engineering technology started as a research program in 2001 focusing on tissue engineering and regenerative medicine based around the proprietary ADAPT® Tissue Engineering Process. The lead program CardioCel® has successfully undergone and completed a number of animal studies and a Phase II human clinical trial. CardioCel® is a cardiovascular scaffold used to repair paediatric heart deformities. These deformities range from routine "hole in the heart" operations to major vessel outflow tract repairs. The CardioCel® scaffold may also be used to repair leaking heart valves in paediatric patients. CardioCel® has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration*, suggesting that CardioCel® facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.
The division is based on the patented ADAPT® Tissue Engineering Process as a platform technology to produce implantable tissue scaffolds for use in various soft tissue repair
applications and for the production of replacement tissue heart valves. The ADAPT® technology is used to process xenograft tissues to produce unique implantable tissue scaffolds that are
compatible with the human body. The technology has a number of advantages over current tissue treatment processes on the market, most notably the reduction of calcification post
implantation and has the potential to replace many of the products that surgeons currently use
for soft tissue repair.

ABN 35 088 221 078

Level 1, 197 Adelaide Terrace

Perth Western Australia 6000

PO Box 6879 East Perth

Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

E info@alliedhealthcaregroup.com.au

distributed by